Redwood Pharma receives its third and last national approval
Redwood Pharma has now also received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to initiate the clinical trial of RP101, the company's new drug candidate for treatment of chronic dry eyes in postmenopausal women. This means that Redwood Pharma has obtained all planned national approvals in Austria, Hungary and Germany.Redwood Pharma’s Phase II clinical trial is a randomized and vehicle (placebo)-controlled multicenter study which will be conducted at clinics in Austria, Hungary and Germany. Patients will be evaluated over 12 weeks and where the primary